MSB 0.00% $1.10 mesoblast limited

Silviu Itescu The Legend, page-422

  1. 258 Posts.
    lightbulb Created with Sketch. 663
    Totally understand why a lot of doctors are skeptical, and fair enough. I think that is in large part because much of medicine is still taught in disease/system silos to put it crudely (evidenced by so many specialties). That makes it difficult to imagine one treatment (e.g. different dosages of MSCs) can be used across different disease compartments e.g. Cardiology, Rheumatology, Gasteroenterology etc. Don't get me wrong, we will always need specialists, but if you take a step back and look at the nexus (or origin) and progression of disease, you will find inflammation plays a major role across many acute and chronic diseases (maybe an Inflammologist will be a thing of the not too distant future, cutting across disease areas). This is the revolution. Targeting diseases at their fundamental level (and aiming to halt progression) as opposed to treating symptomatology in isolation (usually requiring daily medications over the longer term). And the data bank is increasing where cell therapies (e.g. MSC's, plasma infusions etc.) are showing in some instances to have greater efficacy and duration of effect as well as an extremely favourable safety profile.
    Last edited by Martin37: 18/01/22
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.